首页> 外文期刊>Expert opinion on investigational drugs >Experimental therapy in myelofibrosis with myeloid metaplasia
【24h】

Experimental therapy in myelofibrosis with myeloid metaplasia

机译:骨髓纤维化伴髓样化生的实验治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Myelofibrosis with myeloid metaplasia (MMM) is a Philadelphia chromosome-negative myeloproliferative disorder that is characterised by constitutional symptoms,progressive anaemia and extramedullary haemato-poiesis.There are no curative therapies available for patients with MMM apart from stem cell transplantation,which is associated with significant morbidity and mortality,and for which most patients are not suitable candidates.Traditional pharmacological therapy of MMM has focused on the palliation of symptoms associated with myeloproliferation and correction of cyto-poenias.Recently,new findings regarding the molecular basis of MMM and the pathogenesis of the associated bone marrow stromal reaction have provided both basic and clinical researchers with invaluable tools to develop effective targeted therapies for patients with MMM.Several novel treatment strategies are being investigated including antiangiogenic agents,signal transduction inhibitors,inhibitors of fibrogenesis and small-molecule inhibitors of the JAK2~(V617F) mutation.This article reviews the current status of experimental novel therapies for MMM.
机译:骨髓纤维化伴髓样化生(MMM)是费城染色体阴性的骨髓增生性疾病,其特征是体质症状,进行性贫血和髓外造血。除干细胞移植外,没有针对MMM患者的治愈性疗法。 MMM的传统药物治疗主要集中在减轻与骨髓增生相关的症状和纠正细胞性贫血。最近,关于MMM的分子基础和发病机理的新发现相关的骨髓基质反应已为基础研究人员和临床研究人员提供了宝贵的工具,可为MMM患者开发有效的靶向治疗方法。正在研究几种新的治疗策略,包括抗血管生成剂,信号转导抑制剂,纤维生成抑制剂和小肿瘤。 JAK2〜(V617F)突变的l分子抑制剂。本文综述了MMM实验新型疗法的现状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号